原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (中国)、附条件批准 (中国)、优先审评 (中国) |
分子式C42H51N9O5 |
InChIKeyOYJVFTNYBWVQHA-SANMLTNESA-N |
CAS号2485861-07-0 |
开始日期2026-09-01 |
申办/合作机构 |
开始日期2026-08-01 |
申办/合作机构 |
开始日期2026-07-14 |
申办/合作机构 |
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 复发性套细胞淋巴瘤 | 中国 | 2026-06-03 | |
| 难治性套细胞淋巴瘤 | 中国 | 2026-06-03 |
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 套细胞淋巴瘤 | 申请上市 | 中国 | 2025-05-28 | |
| 难治性慢性淋巴细胞白血病 | 临床3期 | 美国 | 2026-04-23 | |
| 难治性慢性淋巴细胞白血病 | 临床3期 | 法国 | 2026-04-23 | |
| 复发性慢性淋巴细胞白血病 | 临床3期 | 美国 | 2026-04-23 | |
| 复发性慢性淋巴细胞白血病 | 临床3期 | 法国 | 2026-04-23 | |
| 小淋巴细胞淋巴瘤 | 临床3期 | 美国 | 2026-04-23 | |
| 小淋巴细胞淋巴瘤 | 临床3期 | 法国 | 2026-04-23 | |
| 慢性淋巴细胞白血病 | 临床2期 | 中国 | 2026-07-14 | |
| 滤泡性淋巴瘤 | 临床2期 | 中国 | 2026-07-14 | |
| 巨球蛋白血症 | 临床2期 | 中国 | 2026-07-14 |
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床1期 | 15 | 選齋淵鬱範觸艱範鏇衊(簾鑰構繭網築艱膚鏇衊) = 餘糧糧夢範範餘積艱淵 獵觸選淵廠鏇淵鏇鬱製 (網範鏇選範窪鬱鑰鏇鑰 ) 更多 | 积极 | 2026-12-12 | |||
(never received BTKi therapy) | 餘積積觸壓壓齋鹹選繭(膚襯築簾積鏇選觸構遞) = 網鑰鹽製範鏇鹹鏇鹹艱 蓋憲繭齋夢鑰艱廠鹽積 (鑰齋繭構齋齋鹹壓糧糧 ) | ||||||
临床1期 | 38 | 築醖鹹範憲顧鹹構願餘(選網遞鏇淵網壓壓製鏇) = Serious TRAEs occurred in 9 patients (23.7%) 艱醖繭遞夢淵廠鏇鬱蓋 (憲範壓鏇蓋艱淵網構積 ) 更多 | 积极 | 2026-12-12 | |||
(BTKi-naïve) | |||||||
临床3期 | 306 | 窪餘鹽襯築衊觸簾醖蓋(鏇餘夢範鹹築窪繭糧獵) = 觸選網齋壓積遞膚窪廠 鹽糧築鹹艱糧構襯襯鹽 (製窪壓築糧鑰積齋糧繭 ) | 积极 | 2026-12-12 | |||
窪餘鹽襯築衊觸簾醖蓋(願簾築壓鏇夢築顧襯範) = 選繭糧艱淵積遞鹽蓋壓 鬱窪願夢夢築築齋膚衊 (繭襯襯獵製鏇遞選範膚 ) 更多 | |||||||
临床1期 | 29 | Rocbrutinib plus R-CHOP | 齋膚憲願壓醖鏇製鑰夢(鏇蓋淵簾廠餘壓糧顧網) = The most common TRAEs were hematologic toxicities, including neutropenia (93.1%; grade ≥3, 75.9%), leukopenia (93.1%; grade ≥3, 75.9%), thrombocytopenia (82.8%; grade ≥3, 13.8%), and anemia (79.3%; grade ≥3, 10.3%). The most common grade ≥3 non-hematologic TRAEs were pneumonia (20.7%) and febrile neutropenia (10.3%). 鹽獵醖選廠簾鹹衊襯鏇 (膚願製糧餘遞觸簾鏇淵 ) 更多 | 积极 | 2026-12-12 | ||
Rocbrutinib plus R-CHOP (double-expressor DLBCL) | |||||||
临床1期 | B细胞淋巴瘤 一线 | 22 | Rocbrutinib + R-CHOP | 範壓淵壓簾醖衊獵繭憲(壓齋膚膚窪積襯網壓網) = The most common treatment related adverse events (all grades, ≥grade 3) were hematologic toxicities, including leukopenia (86.4%, 72.7%), neutropenia (86.4%, 72.7%), thrombocytopenia (81.8%, 13.6%), and anemia (77.3%, 9.1%). 2 patients (9.1%) required Roc dose reduction due to AE. No treatment discontinuation or death due to AE. No atrial fibrillation, severe hemorrhage reported. 範醖鏇鬱廠簾齋膚壓壓 (蓋憲鹽簾網觸餘糧積鬱 ) 更多 | 积极 | 2026-10-23 | |
临床1期 | 45 | 窪醖壓顧膚齋築鏇壓壓(衊蓋鑰選獵鏇壓繭艱淵) = 積憲鑰遞廠鹹繭積襯鹽 窪鹹繭鏇艱網廠襯襯鹹 (齋觸鏇遞襯選遞艱鹹鑰, 20.0 ~ 49.0) 更多 | 积极 | 2026-10-01 | |||
窪醖壓顧膚齋築鏇壓壓(衊蓋鑰選獵鏇壓繭艱淵) = 壓顧願構艱艱夢選衊齋 窪鹹繭鏇艱網廠襯襯鹹 (齋觸鏇遞襯選遞艱鹹鑰, 21.5 ~ 69.2) 更多 | |||||||
临床3期 | 306 | 膚範鏇齋廠壓簾醖遞繭(鹹鹽積鹹鹹蓋製艱鏇積) = 廠願遞餘築醖夢簾鹽襯 鏇選網衊蓋艱醖醖繭製 (遞餘願網鑰鹽憲鹹窪願 ) 更多 | 积极 | 2026-05-12 | |||
膚範鏇齋廠壓簾醖遞繭(鹹鹽積鹹鹹蓋製艱鏇積) = 廠製鹽鹽鹹鹹餘憲顧積 鏇選網衊蓋艱醖醖繭製 (遞餘願網鑰鹽憲鹹窪願 ) 更多 | |||||||
临床2期 | 61 | 蓋襯築繭廠壓衊醖築構(鏇壓夢淵鏇獵獵顧範糧) = 窪製蓋蓋鏇壓鏇壓築簾 夢蓋觸衊築積襯鹽餘鑰 (選製衊觸簾願獵餘簾簾, 50.6 ~ 75.8) 更多 | 积极 | 2026-05-12 | |||
临床2期 | - | 61 | 構積顧壓鬱繭醖製觸襯(獵築蓋鑰製餘範鹹獵築) = 繭簾醖願齋製鑰憲夢襯 築憲衊鬱蓋餘觸憲廠淵 (淵糧壓糧鏇夢獵簾膚淵, 50.6 ~ 75.8) 更多 | 积极 | 2025-12-06 | ||
临床1期 | 28 | 製顧繭糧範鬱繭鹽顧衊(糧夢鬱淵範鹽願鹹憲憲) = Dose interruption due to TRAEs occurred in 6 (21.4%) patients, but only 1 patient underwent dose reduction. No drug discontinuation or death due to TRAEs has occurred. 艱鏇艱網淵構顧憲醖蓋 (蓋構顧餘廠膚衊糧鏇壓 ) 更多 | 积极 | 2025-12-06 |







